Neal Walker - Dec 4, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
INTERIM CEO, Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Dec 4, 2024
Transactions value $
-$76,333
Form type
4
Date filed
12/6/2024, 04:15 PM
Previous filing
Dec 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise $181K +119K +8.59% $1.52 1.5M Dec 4, 2024 Direct
transaction ACRS Common Stock Tax liability -$257K -68.3K -4.55% $3.76 1.43M Dec 4, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Employee Stock Option (right to buy) Options Exercise $0 -119K -100% $0.00 0 Dec 4, 2024 Common Stock 119K $1.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported represents the withholding of shares by the Issuer to satisfy the exercise price and the Reporting Person's tax withholding obligations in connection with the option exercise described in this Form 4.
F2 Fully vested and exercisable.